ALTH Receives Priority Review from FDA for Cancer Drug |
 |
 |
| Tuesday, 26 May 2009 09:25 |
 Allos Therapeutics (NASDAQ:ALTH) Receives Priority Review Designation for Cancer Drug: Filed NDA on 3/25/09 with FDA for pralatrexate in the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). ALTH received a priority (six-month) review designation on 5/26/09 with a PDUFA decision date of 9/24/09. PTCL comprises a biologically diverse group of hematologic malignancies that typically has a worse prognosis than other types of lymphoma and is less responsive to traditional chemotherapy regimens. There are currently no agents approved by the FDA for the treatment of patients with PTCL.
BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
about 27 minutes ago
$AMLN Said to Attract Interest From Pfizer, AstraZeneca - Businessweek http://t.co/PFKT6LE8
about 1 hour ago
Stock Market: Stocks Extend Losing Streak http://t.co/ZmZxvJiO
about 2 hours ago
Cancer Survivors Who Exercise Live Longer http://t.co/U4MhX04a
about 3 hours ago
Colon cancer screenings that don’t require laxatives are almost as effective as colonoscopies and may encourage more tests http://j.m…
about 4 hours ago
Testing a Drug That May Stop Alzheimer’s Before It Starts $RHHBY http://t.co/Wjgw15IS
about 4 hours ago
Two patients get eye stem cells transplanted to restore sight http://t.co/HHYZlFFT
about 4 hours ago
US Senate call to scrap drug patents: http://t.co/W1BOuxJp
about 4 hours ago
http://t.co/MAgh4Xke
Free Phone Trade Alerts
